Navigation Links
Mount Sinai Researchers Succeed in Programming Blood Forming Stem Cells
Date:6/13/2013

hn.mssm.edu/research/institutes/black-family-stem-cell-institute" onclick="linkClick(this.href)">The Black Family Stem Cell Institute at The Mount Sinai Medical Center.

“The combination of gene factors that we used was not composed entirely of the most obvious or expected proteins,” said Dr. Lemischka. “Many investigators have been trying to grow hematopoietic stem cells from embryonic stem cells, but this process has been problematic. Instead, we used mature mouse fibroblasts, picked the right combination of proteins, and it worked.”

“This discovery is just the beginning of something new and exciting and can hopefully be used to identify a treatment for blood disorders,” said Dennis S. Charney, MD, Anne and Joel Ehrenkranz Dean of the Icahn School of Medicine at Mount Sinai and Executive Vice President for Academic Affairs at The Mount Sinai Medical Center.

According to Dr. Pereira, there is a critical shortage of suitable donors for blood stem cell transplants. Donors are currently necessary to meet the needs of patients suffering from blood diseases such as leukemia, aplastic anemia, lymphomas, multiple myeloma and immune deficiency disorders. “Programming of hematopoietic stem cells represents an exciting alternative,” said Pereira.

“Dr. Lemischka and I have been working together for over 20 years in the fields of hematopoiesis and stem cell biology,” said Dr. Moore, senior author of the study. “It is truly exciting to be able to grow these blood forming cells in a culture dish and learn so much from them. We have already started applying this new approach to human cells and anticipate similar success.”

Mount Sinai Innovation Partners is managing the intellectual property for this cell replacement technology on behalf of the Mount Sinai researchers and is actively engaged with commercial collaboration opportunities.


'/>"/>
Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Page: 1 2 3 4 5

Related medicine news :

1. Mount Sinai researchers succeed in programming blood forming stem cells
2. Mount Sinai researchers provide 1st prospective characterization of a genetic subtype of autism
3. The Kravis Children’s Hospital at Mount Sinai Increases Number of Specialties Ranked in U.S. News & World Report “Best Children’s Hospitals”
4. AMTC Sets Up Facebook Contest to Win Two 4-Day Passes to AtlantaFest 2013 at Stone Mountain Park June 12-15th
5. 4 Days - 4 Stages... AtlantaFest Returns to Stone Mountain Park, June 12-15th -- Made Possible This Year by Actors, Models and Talent For Christ
6. Mount Sinai Celebrates ‘Team Science’ at Second-Annual SINAInnovations Conference Nov. 18-19, 2013
7. Christopher Oliver Agency Helps Female Mountain Biking And Outdoor Sports For Women Authority Dirty Jane Transition To New Domain Name
8. Evidence mounts that 4 lifestyle changes will protect heart, reduce your risk of death
9. Stryker Hip Lawsuits Filed in Wake of Rejuvenate and ABG II Hip Stem Recall Continue to Mount in New Jersey Superior Court, Bernstein Liebhard LLP Reports
10. Mount Sinai’s Simulation Lab Proves Effective in Training Anesthesiologists Reentering Practice
11. Intermountain Vein Center Announces Groundbreaking Guidelines in Treatment of Acute Ischemic Stroke
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/4/2015)... Malibu, CA (PRWEB) May 04, 2015 ... of KissSafe™ oral antiseptic breath spray. KissSafe™ is ... making kissing a safer experience while adding fresh ... that safely and effectively kills germs in the ... kissing. It also contains ingredients that possess additional ...
(Date:5/4/2015)... May 04, 2015 Leonardo J. Lozada, ... chief physician executive, and William C. Daniel, M.D., Saint ... accepted personal invitations from the Secretary of the Air ... (NSF) at the Air War College, Maxwell Air Force ... influential citizens to senior U.S. and international officers and ...
(Date:5/4/2015)... May 04, 2015 The University ... today launched a new initiative at UC Davis ... generation of physicians committed to advancing Latino health. ... Medicos, or Preparing Students to Be Physicians, (“Prep ... will provide scholarships, mentorship and internship opportunities, a ...
(Date:5/4/2015)... 04, 2015 Takeda Pharmaceuticals Corp. has ... settle thousands of Actos lawsuits ( http://www.theactoslawsuitcenter.com/ ) ... risk that a patient will develop bladder cancer. According ... 95% of those eligible for the Actos settlement accept ... cancer cases currently pending in courts around the country, ...
(Date:5/4/2015)... McNeil & Company , a nationwide ... coverage for its Emergency Services Insurance Program ... and proactive risk management to the emergency services industry. ... providing our customers with unparalleled service and the best ... are excited to launch over 100 new enhancements that ...
Breaking Medicine News(10 mins):Health News:80 Million Germs from Kissing - Introducing KissSafe™ 2Health News:Saint Luke’s Health System Leadership Selected to Attend National Security Forum 2Health News:New UC Davis Program Targets Next Generation of Physicians to Advance Latino Health 2Health News:New UC Davis Program Targets Next Generation of Physicians to Advance Latino Health 3Health News:New UC Davis Program Targets Next Generation of Physicians to Advance Latino Health 4Health News:New UC Davis Program Targets Next Generation of Physicians to Advance Latino Health 5Health News:Actos Lawsuit Settlement: Takeda Pharmaceutical Co. to Pay As Much As $2.4 Billion to Resolve Claims Alleging Actos Causes Bladder Cancer 2Health News:Actos Lawsuit Settlement: Takeda Pharmaceutical Co. to Pay As Much As $2.4 Billion to Resolve Claims Alleging Actos Causes Bladder Cancer 3Health News:Insurance Leader McNeil & Company Expands Coverage for Emergency Services Insurance Program (ESIP), Launches Enhancements to Property and Casualty Insurance Package 2Health News:Insurance Leader McNeil & Company Expands Coverage for Emergency Services Insurance Program (ESIP), Launches Enhancements to Property and Casualty Insurance Package 3
... Food and Drug Administration (FDA) have approved the drug Femara ... breast cancer among post menopausal women//. ,Various studies ... result of these studies was published in the December 29 ... said that the Novartis drug Femara was very efficient in ...
... of swallows in Malawi had raised fears about the possibility of ... // have revealed a negative bird flu infection status of ... ,"We have tested samples that were sent to us ... swallows, which were dying in large numbers. We don't know what ...
... enterotoxin produced by the bacteria Vibrio cholerae, which leads to ... has occurred in two cities in // ... infected with the bacteria in two districts of Chikomba and ... is high in conditions where treatment is not given. The ...
... in attitudes toward circumcision in Swaziland, which has one of ... one of the highest HIV prevalence rates. ... sudden comeback in the country since the publication of a ... risk of contracting HIV. ,According to the ...
... children is a major health hazard. More-so when homes use ... lead // poisonings in children, by suggesting new requirements ... years, Lead, a highly toxic metal has been used as ... spectrum of health problems ranging from cognitive impairment and learning ...
... Kerr has urged to increase awareness of organ donation among ... loss dying // due to organ failure and non-availability ... heavy human loss of young people and their lives depend ... Donor cards and registration with NHS organ donor register, which ...
Cached Medicine News:Health News:Men queue up for Circumcision In Swaziland To Prevent HIV/AIDS 2Health News:Child-friendly initiative For Lead-Based Paint Work: EPA, USA 2
(Date:5/4/2015)... 4, 2015  Oncobiologics, Inc., a biotherapeutics company ... biosimilars, has completed the construction of its GMP ... Cranbury, New Jersey . ... is designed to utilize multiple technologies that enable ... Through the use of the latest single-use technologies, ...
(Date:5/4/2015)... May 4, 2015   HeartWare International, Inc . (NASDAQ: ... circulatory support technologies that are revolutionizing the treatment of advanced ... Godshall , is scheduled to present at the Bank of ... Las Vegas on Thursday, May 14, 2015, at ... webcast of the Company,s presentation at the conference will be ...
(Date:5/4/2015)... May 4, 2015  CytRx Corporation (Nasdaq: ... specializing in oncology, today announced an interim analysis ... studies pairing aldoxorubicin with either gemcitabine or ifosfamide. ... ifosfamide with escalating doses of aldoxorubicin. The combinations ... the lowest dose level of aldoxorubicin (170 mg/m2), ...
Breaking Medicine Technology:Oncobiologics opens commercial launch manufacturing facility in Cranbury, New Jersey 2Oncobiologics opens commercial launch manufacturing facility in Cranbury, New Jersey 3HeartWare Presentation At Bank Of America Merrill Lynch 2015 Health Care Conference To Be Webcast 2CytRx Reports Aldoxorubicin Demonstrates Both Tumor Shrinkage and Improved Quality of Life in Chemotherapy Resistant Cancers 2CytRx Reports Aldoxorubicin Demonstrates Both Tumor Shrinkage and Improved Quality of Life in Chemotherapy Resistant Cancers 3CytRx Reports Aldoxorubicin Demonstrates Both Tumor Shrinkage and Improved Quality of Life in Chemotherapy Resistant Cancers 4CytRx Reports Aldoxorubicin Demonstrates Both Tumor Shrinkage and Improved Quality of Life in Chemotherapy Resistant Cancers 5CytRx Reports Aldoxorubicin Demonstrates Both Tumor Shrinkage and Improved Quality of Life in Chemotherapy Resistant Cancers 6CytRx Reports Aldoxorubicin Demonstrates Both Tumor Shrinkage and Improved Quality of Life in Chemotherapy Resistant Cancers 7
... SAN DIEGO, INDIANAPOLIS and CAMBRIDGE, Mass., March 31 ... Lilly and Company (NYSE: LLY ) and ... positive results from DURATION-2, the second in a series ... once weekly, an investigational diabetes therapy, as compared to ...
... new study, published in the Journal of Medicinal ... 8 grams (1/3 ounce) of "Sun Chlorella A" daily ... total cholesterol, and fasting blood glucose levels.For a 12-week ... A" tablets each morning and evening. Seventeen subjects ...
Cached Medicine Technology:Exenatide Once Weekly Provided Superior Glucose Control With Weight Loss Compared to Sitagliptin or Pioglitazone in Head-to-Head DURATION-2 Study 2Exenatide Once Weekly Provided Superior Glucose Control With Weight Loss Compared to Sitagliptin or Pioglitazone in Head-to-Head DURATION-2 Study 3Exenatide Once Weekly Provided Superior Glucose Control With Weight Loss Compared to Sitagliptin or Pioglitazone in Head-to-Head DURATION-2 Study 4Exenatide Once Weekly Provided Superior Glucose Control With Weight Loss Compared to Sitagliptin or Pioglitazone in Head-to-Head DURATION-2 Study 5Exenatide Once Weekly Provided Superior Glucose Control With Weight Loss Compared to Sitagliptin or Pioglitazone in Head-to-Head DURATION-2 Study 6First Human Study to Show 'Sun Chlorella A' Supports Heart Health 2
This standard tying forcep is curved with 5mm titanium coated platforms. Length 85 mm....
Catalano curved tying forcep has 6 mm V-grove tying platform. Overall length 100 mm....
Kelman - McPherson tying forceps with serrated handle, platform 4 mm and overall length of 85 mm....
Troutman tying forceps are curved, delicate, bullet shape, with tying platforms. Flat pattern. Ultra fine platforms ideal for 10-0 or 11-0 suture material. Platforms fully meet to hold suture firmly....
Medicine Products: